CY1105816T1 - Χρηση θepαπειας με νευροτοξινη για την αντιμετωπιση της κατακρατησης ουρων - Google Patents

Χρηση θepαπειας με νευροτοξινη για την αντιμετωπιση της κατακρατησης ουρων

Info

Publication number
CY1105816T1
CY1105816T1 CY20061101731T CY061101731T CY1105816T1 CY 1105816 T1 CY1105816 T1 CY 1105816T1 CY 20061101731 T CY20061101731 T CY 20061101731T CY 061101731 T CY061101731 T CY 061101731T CY 1105816 T1 CY1105816 T1 CY 1105816T1
Authority
CY
Cyprus
Prior art keywords
contention
treat urinary
toxin
suppository
neurotoxin therapy
Prior art date
Application number
CY20061101731T
Other languages
English (en)
Inventor
Richard A. Schmidt
Original Assignee
The Regents Of The University Of Colorado
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21978526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105816(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of Colorado filed Critical The Regents Of The University Of Colorado
Publication of CY1105816T1 publication Critical patent/CY1105816T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Η χρήση τοξίνης αλλαντίασης, ιδίως τοξίνης τύπου Α, στην παρασκευή φαρμακευτικής σύνθεσης για την κατακράτηση ούρων η οποία είναι δευτεροπαθής σε υπερτροφικό αυχένα ουροδόχου κύστης ή σε σπαστικό σφιγκτήρα. Η τοξίνη αλλαντίασης μπορεί να τυποποιηθεί σε φαρμακευτικά αποδεκτό σκεύασμα για παράδειγμα ως υγρό, σκόνη, κρέμα, γαλάκτωμα, καταπότιο, τροχίσκο, υπόθετο, εναιώρημα, ή διάλυμα, και να χορηγηθεί στην ουροποιητική οδό άρρενος ή θήλεος ανθρώπου.
CY20061101731T 1997-07-15 2006-11-30 Χρηση θepαπειας με νευροτοξινη για την αντιμετωπιση της κατακρατησης ουρων CY1105816T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5258097P 1997-07-15 1997-07-15
EP98933345A EP1011695B2 (en) 1997-07-15 1998-07-15 Use of neurotoxin therapy for treatment of prostate disorders

Publications (1)

Publication Number Publication Date
CY1105816T1 true CY1105816T1 (el) 2011-02-02

Family

ID=21978526

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20061101731T CY1105816T1 (el) 1997-07-15 2006-11-30 Χρηση θepαπειας με νευροτοξινη για την αντιμετωπιση της κατακρατησης ουρων
CY20101100157T CY1109827T1 (el) 1997-07-15 2010-02-17 Χρηση της αλλαντοτοξινης για την αγωγη δυσκολα αντιμετωπισιμης δυσλειτουργιας κενωσης
CY20121100474T CY1113355T1 (el) 1997-07-15 2012-05-25 Χρηση θεραπειας νευροτοξινης για θεραπευτικη αγωγη ουρολογικων και σχετικων διαταραχων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20101100157T CY1109827T1 (el) 1997-07-15 2010-02-17 Χρηση της αλλαντοτοξινης για την αγωγη δυσκολα αντιμετωπισιμης δυσλειτουργιας κενωσης
CY20121100474T CY1113355T1 (el) 1997-07-15 2012-05-25 Χρηση θεραπειας νευροτοξινης για θεραπευτικη αγωγη ουρολογικων και σχετικων διαταραχων

Country Status (16)

Country Link
US (5) US6365164B1 (el)
EP (8) EP1637157A1 (el)
JP (9) JP3692033B2 (el)
KR (1) KR100544060B1 (el)
CN (5) CN1321683C (el)
AT (5) ATE339220T1 (el)
AU (2) AU743085B2 (el)
CA (5) CA2521392A1 (el)
CY (3) CY1105816T1 (el)
DE (4) DE69833059T3 (el)
DK (6) DK1502601T4 (el)
ES (6) ES2268567T5 (el)
HK (4) HK1091750A1 (el)
LU (2) LU92055I2 (el)
PT (5) PT2145629E (el)
WO (1) WO1999003483A1 (el)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) * 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
DK1502601T4 (da) 1997-07-15 2010-11-08 Univ Colorado Anvendelse af neurotoksin-terapi til behandling af urinretention
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
RU2242153C2 (ru) * 1999-04-01 2004-12-20 Хилинг Спортс Лимитед. Устройство для катания на пятке и способ
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6773711B2 (en) 2000-02-15 2004-08-10 Allergan, Inc. Botulinum toxin therapy for Hashimoto's thyroiditis
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
AU2002315814B2 (en) * 2001-07-10 2007-05-31 Astellas Pharma Inc. Medicinal composition for treatment of interstitial cystitis
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US7063860B2 (en) * 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
NZ533309A (en) 2001-11-15 2006-03-31 Micro Algae Corp Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
WO2004010934A2 (en) * 2002-07-29 2004-02-05 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
GB2398636A (en) * 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
US8071550B2 (en) * 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
MXPA05009425A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US7354740B2 (en) 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
US20050096549A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transperineal delivery of a denervating agent to the prostate gland
US20050096629A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transurethral delivery of a denervating agent to the prostate gland
US20050096550A1 (en) * 2003-10-31 2005-05-05 Medtronic, Inc. Techniques for transrectal delivery of a denervating agent to the prostate gland
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
BRPI0510759A (pt) * 2004-05-07 2007-11-20 Phytotox Ltd método de facilitar a cura de um ferimento
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
PL1776137T3 (pl) 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
US20080102090A1 (en) 2004-08-04 2008-05-01 Naveed Panjwani Pharmaceutical Compositon Containing Botulinum Neurotoxin A2
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
CA2610885A1 (en) * 2005-06-07 2006-12-14 David R. Staskin Injection guidance system and method
US20070038089A1 (en) * 2005-06-29 2007-02-15 Olympus Medical Systems Corp. Transurethral diagnostic method and treatment method using ultrasonic endoscope
AU2006346369B2 (en) * 2005-07-18 2013-02-21 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2008045107A2 (en) 2005-12-01 2008-04-17 University Of Massachusetts Lowell Botulinum nanoemulsions
US20090312696A1 (en) * 2005-12-28 2009-12-17 Copa Vincent G Devices, Systems, and Related Methods for Delivery of Fluid to Tissue
WO2007106874A2 (en) * 2006-03-14 2007-09-20 Autocraft Industries, Inc. Improved wheelchair
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
WO2008030638A2 (en) * 2006-05-16 2008-03-13 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
US20100172943A1 (en) 2006-12-01 2010-07-08 Anterios, Inc. Peptide nanoparticles and uses therefor
EP2583687B1 (en) * 2007-02-15 2014-08-27 Allergan, Inc. Use of botulinum toxin for treating hyperhydrosis
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
SG185338A1 (en) 2007-10-23 2012-11-29 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
CN105147608B (zh) * 2008-06-26 2019-12-10 安特里奥公司 真皮递送
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP2376104A4 (en) * 2008-12-15 2014-09-10 Protox Therapeutics Inc Method of treating prostatitis with proaeryslyin, modified pore-forming protein
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
US8133491B1 (en) 2009-01-30 2012-03-13 The University Of Toledo Compositions and methods for treatment of hyperplastic disorders
US20120021969A1 (en) 2009-03-06 2012-01-26 Allergan, Inc. Prosthetic implant shell
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
EP2482838A4 (en) 2009-09-30 2013-04-10 Toxcure Inc USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE
WO2012024286A2 (en) 2010-08-18 2012-02-23 Medtronic, Inc. Urgency therapy with neuromodulation and c-afferent nerve desensitization
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US20120207733A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
EP2729163A1 (en) 2011-07-08 2014-05-14 Allergan, Inc. Method for treatment of autonomic nervous system disorders
KR20140054055A (ko) 2011-07-14 2014-05-08 알러간, 인코포레이티드 성행위와 관련된 실금의 치료방법
MX2014000612A (es) 2011-07-20 2014-02-27 Allergan Inc Toxinas botulinicas para usar en un metodo para el tratamiento de depositos adiposos.
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
EP2836200B1 (en) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
ES2944536T3 (es) * 2015-02-03 2023-06-22 Hoeganaes Ab Publ Composición de metal en polvo para fácil mecanización
MA45492A (fr) 2016-06-23 2019-05-01 Hopitaux Paris Assist Publique Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
RU2687106C1 (ru) * 2017-12-19 2019-05-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ лечения синдрома гиперактивного мочевого пузыря
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
CN110935009B (zh) * 2019-12-24 2023-07-11 云南南诏药业有限公司 科博肽制剂在制备治疗痔疮药物中的应用
RU2768606C1 (ru) * 2021-04-16 2022-03-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр колопроктологии имени А.Н. Рыжих" Министерства здравоохранения Российской Федерации Способ комбинированного хирургического лечения хронической анальной трещины со спазмом сфинктера методом иссечения трещины в сочетании с инъекцией ботулинического токсина типа А в дозировке 40 ЕД во внутренний анальный сфинктер под ультразвуковой навигацией

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932936A (en) † 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
JPH0642950Y2 (ja) * 1988-10-15 1994-11-09 株式会社マイコー ケース固定装置
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
EP0702559B1 (en) 1993-06-10 2003-03-19 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5437291A (en) † 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1147776B1 (en) 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
DK1502601T4 (da) 1997-07-15 2010-11-08 Univ Colorado Anvendelse af neurotoksin-terapi til behandling af urinretention
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
JP3655061B2 (ja) * 1997-07-31 2005-06-02 株式会社ニデック 紫外線吸収性基材
JP2000214813A (ja) * 1999-01-22 2000-08-04 Mercury Enterprise:Kk 二輪及び三輪車輌・トラック・四輪車両へ搭載可能な可動式省エネ広告塔
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2002132198A (ja) * 2000-10-25 2002-05-09 Sukenori Kiuchi 三輪自転車一体型移動式回転広告塔
JP2002306290A (ja) * 2001-04-19 2002-10-22 Takumi:Kk ターンテーブル
JP2007037725A (ja) * 2005-08-02 2007-02-15 Masahiro Matsubara 多機能立方体展示ユニット
JP3121792U (ja) * 2005-10-28 2006-06-01 株式会社イマジンクリエイション ラック付３ｄレンズ使用立体型看板

Also Published As

Publication number Publication date
CA2521392A1 (en) 1999-01-28
AU743085B2 (en) 2002-01-17
CN1270527A (zh) 2000-10-18
JP2005089479A (ja) 2005-04-07
ES2256945T5 (es) 2010-03-26
ES2255025T3 (es) 2006-06-16
DK2145629T3 (da) 2012-05-29
ES2450747T3 (es) 2014-03-25
DK1475099T3 (da) 2006-03-13
AU8300798A (en) 1999-02-10
LU92250I2 (fr) 2013-09-10
EP1011695B1 (en) 2006-03-22
JP4672676B2 (ja) 2011-04-20
EP1502601B1 (en) 2006-09-13
DK1658858T3 (da) 2010-04-06
KR100544060B1 (ko) 2006-01-23
ES2255025T5 (es) 2014-06-16
DE69833059D1 (de) 2006-02-02
EP1011695A4 (en) 2004-05-26
CA2505930A1 (en) 1999-01-28
DE69841291D1 (de) 2009-12-31
CN1651074A (zh) 2005-08-10
JP4815468B2 (ja) 2011-11-16
ES2385130T3 (es) 2012-07-18
AU2005234633A1 (en) 2005-12-15
AU2005234633B2 (en) 2007-04-19
CA2570406C (en) 2012-02-14
EP1658858B2 (en) 2014-03-26
JP3955061B2 (ja) 2007-08-08
EP1011695B2 (en) 2009-11-04
CN1480212A (zh) 2004-03-10
JP2007126477A (ja) 2007-05-24
DE69833942D1 (de) 2006-05-11
EP1658858A3 (en) 2006-07-05
JP4053559B2 (ja) 2008-02-27
ATE448792T1 (de) 2009-12-15
CN1803189B (zh) 2010-05-26
JP4696082B2 (ja) 2011-06-08
US20040259788A1 (en) 2004-12-23
HK1091750A1 (en) 2007-01-26
JP2006104221A (ja) 2006-04-20
CN1135988C (zh) 2004-01-28
DK1949909T3 (en) 2014-03-24
EP1011695A1 (en) 2000-06-28
US7153514B2 (en) 2006-12-26
PT1658858E (pt) 2010-02-26
EP1658858B1 (en) 2009-11-18
JP2005089478A (ja) 2005-04-07
EP1637157A1 (en) 2006-03-22
LU92055I2 (fr) 2013-10-10
PT1949909E (pt) 2014-03-11
ES2268567T3 (es) 2007-03-16
CA2296720A1 (en) 1999-01-28
DK1502601T4 (da) 2010-11-08
WO1999003483A1 (en) 1999-01-28
JP3692033B2 (ja) 2005-09-07
DE69835911T2 (de) 2007-01-11
EP1949909B1 (en) 2014-01-08
ES2336924T3 (es) 2010-04-19
US6365164B1 (en) 2002-04-02
PT1502601E (pt) 2006-12-29
DE69835911D1 (de) 2006-10-26
US7429387B2 (en) 2008-09-30
DK1502601T3 (da) 2007-01-15
HK1119396A1 (en) 2009-03-06
US20050159337A1 (en) 2005-07-21
CA2570406A1 (en) 1999-01-28
HK1080377A1 (en) 2006-04-28
DE69833059T2 (de) 2006-08-03
JP2006063089A (ja) 2006-03-09
DK1658858T4 (da) 2014-04-07
US6667041B2 (en) 2003-12-23
CN1480212B (zh) 2013-12-04
US20020025327A1 (en) 2002-02-28
JP5005753B2 (ja) 2012-08-22
EP2145629A2 (en) 2010-01-20
CN1321683C (zh) 2007-06-20
DE69833942T2 (de) 2006-09-07
AU2005234633B9 (en) 2009-09-03
DK1011695T3 (da) 2006-05-01
ATE320815T1 (de) 2006-04-15
EP2145629B1 (en) 2012-04-04
EP2145629A3 (en) 2010-06-09
CA2505933C (en) 2008-09-30
JP2007091756A (ja) 2007-04-12
JP2008208136A (ja) 2008-09-11
EP1475099B1 (en) 2005-12-28
DE69833942T3 (de) 2010-06-10
ATE339220T1 (de) 2006-10-15
US7001602B2 (en) 2006-02-21
EP1502601B2 (en) 2010-07-21
CA2296720C (en) 2008-01-29
DK1475099T4 (da) 2014-05-19
EP1475099B2 (en) 2014-04-09
EP2246066A1 (en) 2010-11-03
PT2145629E (pt) 2012-04-16
ATE314085T1 (de) 2006-01-15
ES2336924T5 (es) 2014-04-30
PT1011695E (pt) 2006-07-31
DK1011695T4 (da) 2010-02-01
EP1502601A1 (en) 2005-02-02
DE69833059T3 (de) 2014-12-18
CA2505933A1 (en) 1999-01-28
HK1064044A1 (en) 2005-01-21
JP2001510163A (ja) 2001-07-31
CN1803189A (zh) 2006-07-19
CN1939531A (zh) 2007-04-04
CY1109827T1 (el) 2014-09-10
ATE552006T1 (de) 2012-04-15
AU2005234633C1 (en) 2011-02-10
CA2505930C (en) 2008-01-29
CN100518816C (zh) 2009-07-29
KR20010021941A (ko) 2001-03-15
EP1949909A1 (en) 2008-07-30
US20040126380A1 (en) 2004-07-01
JP2010043127A (ja) 2010-02-25
EP1475099A1 (en) 2004-11-10
ES2268567T5 (es) 2010-11-02
DE69835911T3 (de) 2011-01-13
CY1113355T1 (el) 2016-06-22
ES2256945T3 (es) 2006-07-16
EP1658858A2 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
CY1105816T1 (el) Χρηση θepαπειας με νευροτοξινη για την αντιμετωπιση της κατακρατησης ουρων
SE9703226D0 (sv) New pharmaceutical composition
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
BR9810089A (pt) Processo para tratar uma fêmea humana sofrendo de dismenorréia, composição farmaceuticamente aceitável, e, dispositivo para suprir um agente farmacêutico a um útero de fêmea
GB9423911D0 (en) Therapeutic agents
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
BR9712321A (pt) Aminotiofenocarboxamidas
TR200000369T2 (tr) Romatizmal hastalıkların tedavisinde kullanılmak üzere kombine farmasötik preparatların üretilmesi.
ES2160821T3 (es) Uso de una composicion que comprende amoxicilina y acido clavulanico para la produccion de un medicamento para el tratamiento de infecciones bacterianas en pacientes pediatricos.
ATE295160T1 (de) Zusammensetzungen enthaltend isovalerianamide zusammen mit ibuprofen
DE69619052D1 (de) Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung
HUP9902094A2 (hu) PGE-1-tartalmú liofilizált liposzómák erekciós zavar kezelésében való alkalmazásra
KR940018087A (ko) 진통제 및 소염제로서의 6-클로로-5-플루오로-3-(2-테노일)-2-옥신돌-ⅰ-카복스아미드
ATE231388T1 (de) Lang wirksames mittel zur rektalen verabreichung
ES2192840T3 (es) Laxante osmotico no fermentado para tratar y prevenir cancer colorrectal.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
PT986386E (pt) Uso de derivados heterociclicos aromaticos com azoto no tratamento topico de doencas dos tecidos epiteliais
SE0001916D0 (sv) Novel formulation
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
HUP0302984A2 (hu) Buprenorphin felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
TR199900013T2 (xx) Yeni bile�ikler.
SE9700617D0 (sv) New composition
Martorana et al. Treatment of urinary tract infections with ciprofloxacin
GEU2000587Y (en) Medicinal Ointment Turmanidze-Burduli Derma
RU96122712A (ru) Способ коррекции микрофлоры вагины